SPVN20/30
Not Specified (Pipeline includes dry AMD/Geographic Atrophy)
Pre-clinicalActive
Key Facts
Indication
Not Specified (Pipeline includes dry AMD/Geographic Atrophy)
Phase
Pre-clinical
Status
Active
Company
About SparingVision
SparingVision is a French biotech innovator leading a paradigm shift in ocular disease treatment through mutation-independent genomic medicines. Its lead asset, SPVN06, is a neuroprotective gene therapy for IRDs currently in clinical trials, with a second program, SPVN20/30, in development. The company leverages AAV-based gene therapy to restore physiological mechanisms in the retina, targeting large patient populations underserved by single-gene approaches. Founded in 2016, SparingVision combines deep ophthalmic research expertise with a clinical-stage pipeline to address significant unmet needs in retinal degeneration.
View full company profile